Awardee OrganizationMEDICAL UNIVERSITY OF SOUTH CAROLINA
Description
Abstract Text
Description (From the Applicant's Abstract): Microglia, the principal immune
effector cells of the brain, play an important role in the regulation of the
immunologic microenvironment within the CNS. They lie dormant until the
integrity of the CNS is challenged by injury, infection or disease processes
and when chronically activated, secrete a number of inflammatory mediators
including cytokines and tissue damaging free radicals as part of the pathogenic
mechanism common to a variety of CNS disorders including stroke, Alzheimer's
Disease, AIDS dementia and demyelinating diseases such as multiple sclerosis. A
mechanistic understanding of the process of microglial activation is,
therefore, crucial for devising therapeutic strategies to suppress
neuroinflammation. This project tests the hypothesis that signal transduction
pathways mediated by members of the mitogen-activated protein kinase (MAPK)
family play a key role in microgiial activation and the induction of
inflammatory responses. Primary cultures of rat brain microglia wili be used as
a model to accomplish the following objectives.
The activities and the roles of MAPK cascades (i.e., extracellular
signal-regulated kinase or ERK, p38 MAPK and c-Jun N-terminal kinase or JNK)
will be investigated in microglia activated in response to endotoxin and
receptor (CD40) ligation. The effects of pharmacological inhibitors of MAPKs on
the expression of microglial antigens (i.e., MHC class 11, B7 and CD40),
cytokines (i.e., TNFa, IL-1, IL-6) and inducible nitric oxide synthase (iNOS)
will be determined by immunochemical and RT-PCR techniques.
Possible isoforrn-specific roles and down-stream targets of p38 MAPK and JNK in
inducing cytokine and iNOS gene expression will be characterized in transient
transfection studies using molecular mutants of the kinases along with iNOS and
cytokine gene promoter constructs.
The suppressive effects of the kinase inhibitors on activation-associated
microglial functions; i.e., targeting of oligodendrocytes and myelin
phagocytosis will be tested using in vitro models.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
CD40 moleculeJUN kinaseMHC class II antigencell cell interactionendotoxinsenzyme activityenzyme induction /repressionenzyme inhibitorsimmunocytochemistryinterleukin 1interleukin 6laboratory ratmicrogliamitogen activated protein kinasemixed tissue /cell culturemyelinneuroimmunomodulationnitric oxide synthaseoligodendrogliaphagocytosispolymerase chain reactionsurface antigenstumor necrosis factor alpha
National Institute of Neurological Disorders and Stroke
CFDA Code
853
DUNS Number
183710748
UEI
NHV3GTWSALA7
Project Start Date
15-April-2001
Project End Date
31-March-2006
Budget Start Date
01-April-2004
Budget End Date
31-March-2006
Project Funding Information for 2004
Total Funding
$214,500
Direct Costs
$150,000
Indirect Costs
$64,500
Year
Funding IC
FY Total Cost by IC
2004
National Institute of Neurological Disorders and Stroke
$214,500
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01NS041035-04
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01NS041035-04
Patents
No Patents information available for 5R01NS041035-04
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01NS041035-04
Clinical Studies
No Clinical Studies information available for 5R01NS041035-04
News and More
Related News Releases
No news release information available for 5R01NS041035-04
History
No Historical information available for 5R01NS041035-04
Similar Projects
No Similar Projects information available for 5R01NS041035-04